Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Director sold 30,000 shares at an average $90.05 ($2,701,582)
  2. 4 Other disposition 10% owner disposed of 383,411 shares (other)
  3. 4 Open-market sale 10% owner sold 64,624 shares at an average $80.14 ($5,179,285)
  4. 4/A Open-market sale Chief Medical Officer sold 17,500 shares at an average $19.44 ($340,168)
  5. 4/A Open-market sale Chief Medical Officer sold 17,500 shares at an average $18.45 ($322,834)
  6. 4/A Open-market sale Chief Medical Officer sold 17,500 shares at $18.07 ($316,157)
  7. 4/A Shares withheld for taxes COO and Secretary gave up 1,954 shares (to pay taxes)
  8. 4 Open-market sale Director sold 30,000 shares at $70.05 ($2,101,590)
  9. 4 Open-market sale Director sold 10,000 shares at $60.03 ($600,310)
  10. 8-K Event Other events
  11. 4 Open-market sale Director sold 10,000 shares at $50.18 ($501,830)
  12. 10-Q Report Quarterly Report
  13. 8-K Event Results of operations
  14. 4 Open-market sale Chief Medical Officer sold 52,906 shares at an average $40.74 ($2,155,603)
  15. 8-K Event Material agreement · Regulation FD disclosure · Other events
  16. 3 Insider Initial Statement of Ownership
  17. SC 13G Stake Amended Statement of Ownership
  18. 4 Open-market sale Chief Medical Officer sold 3,689 shares at $31.00 ($114,359)
  19. 4 Shares withheld for taxes Chief Medical Officer gave up 1,954 shares (to pay taxes)
  20. 4 Shares withheld for taxes COO and Secretary gave up 1,954 shares (to pay taxes)

Page 27 of 40 · 789 filings